|
|
|
|
|
|
|
|
CNW Group
(press release)
TORONTO, Jan. 9, 2017 /CNW/ - Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50% of patients within five years.
The findings, published online today in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated cancers right from the get-go and therefore are resistant to therapy right up front, says co-principal investigator Dr. Robert Bristow, clinician-scientist at Princess Margaret Cancer Centre, University Health Network. He talks about the research at https://youtu.be/dXlntpaWtaI....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.